Share This Page
Drug Price Trends for NDC 72888-0183
✉ Email this page to a colleague
Average Pharmacy Cost for 72888-0183
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BUPRENORPHINE 8 MG TABLET SL | 72888-0183-30 | 0.70747 | EACH | 2025-11-19 |
| BUPRENORPHINE 8 MG TABLET SL | 72888-0183-30 | 0.71108 | EACH | 2025-10-22 |
| BUPRENORPHINE 8 MG TABLET SL | 72888-0183-30 | 0.71273 | EACH | 2025-09-17 |
| BUPRENORPHINE 8 MG TABLET SL | 72888-0183-30 | 0.72097 | EACH | 2025-08-20 |
| BUPRENORPHINE 8 MG TABLET SL | 72888-0183-30 | 0.73162 | EACH | 2025-07-23 |
| BUPRENORPHINE 8 MG TABLET SL | 72888-0183-30 | 0.74966 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72888-0183
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 72888-0183
Introduction
The drug designated by NDC 72888-0183 pertains to a specific pharmaceutical product regulated within the United States. Given the critical role of medication pricing and market dynamics in healthcare decision-making, this analysis offers a comprehensive evaluation of the current market landscape, competitive positioning, and future price trajectories. Leveraging recent industry trends, regulatory updates, and pricing data, this report aims to inform stakeholders—including pharmaceutical companies, healthcare providers, and investors—about strategic considerations surrounding this drug.
Product Overview and Regulatory Background
NDC 72888-0183 refers to [Exact Drug Name, if available], a [drug class or therapeutic area], indicated for [primary medical indication]. It was approved by the FDA in [year], with a notable registration status and labeling information accessible through the FDA's database. As a [type of medication—biosimilar, branded, generic], its market entry timing and competitive landscape are pivotal for pricing strategies.
The approval details, including the drug’s labeling, patent status, and exclusivity periods, establish foundational understanding for market projections. Recent regulatory updates, including patent litigations and potential biosimilar entrants, influence the competitive environment.
Current Market Landscape
Market Size and Revenue Estimates
The therapeutic area served by NDC 72888-0183 has demonstrated consistent growth, driven by factors such as rising patient populations, unmet medical needs, and evolving clinical guidelines. According to IQVIA data, the specific segment accounts for approximately [$X billion] in annual sales with a compound annual growth rate (CAGR) of [Y]% over the past five years.
The initial market penetration of this drug has been robust based on initial pricing, payer acceptance, and formulary placements. Estimates suggest annual revenue for this product in the range of [$X million to $Y million], with projections indicating potential expansion as insurance coverage broadens and clinical acceptance deepens.
Competitive Positioning
The market features several key competitors, including [list of major equivalents or competitors]. The drug’s unique attributes, such as improved efficacy, reduced side effects, or convenience, bolster its market share. Patent protection until [year] or exclusivity periods are critical determinants of pricing power.
Biosimilar development within this space presents imminent threats. Notably, pending biosimilar entries could exert downward pressure on prices, especially post-patent expiration.
Pricing Analysis
Historical Pricing Trends
The existing wholesale acquisition cost (WAC) for NDC 72888-0183 has been approximately [$X per unit/administration], with average patient out-of-pocket costs varying based on insurance coverage and negotiated discounts. Since market entry, price adjustments have occurred primarily due to inflation, supply chain factors, and competitive pressures.
The average list price for similar drugs within the segment has ranged between [$Y to $Z], illustrating a relatively stable or slightly declining trend due to biosimilar competition and payer negotiations.
Reimbursement and Payer Dynamics
Reimbursement rates significantly influence net prices. Payer contracts and formulary placements determine the actual acquisition costs faced by providers. Medicaid and Medicare-dominated segments typically negotiate lower prices, exerting a downward influence on overall pricing outlooks.
Recent policy pressures, including the Biden Administration's focus on drug pricing transparency and value-based arrangements, further impact future pricing strategies. Manufacturers are increasingly adopting value-based pricing models linking reimbursement to clinical outcomes.
Future Price Projections
Factors Influencing Price Trajectory
-
Patent and Exclusivity Expirations: The expiration of patent protection around [year] could lead to a 20-40% reduction in list price, contingent on biosimilar or generic market entry.
-
Biosimilar Market Entry: Estimated biosimilar launches in [region or timeframe] are projected to cause price erosion of approximately 30-50%. The level of price reduction depends on biosimilar competitiveness, payer uptake, and manufacturing costs.
-
Market Penetration and Adoption: As the drug gains wider acceptance and formulary coverage expands, prices may stabilize or increase marginally due to supply chain factors.
-
Regulatory and Policy Environment: Anticipated legislative measures targeting pharmaceutical pricing, such as inflation caps and Medicare negotiation authority, could impose external downward pressure on prices.
Quantitative Price Projections
Based on current trends and assuming typical biosimilar competition timelines, the following projections are relevant:
-
Short-term (1-3 years): List prices are expected to remain relatively stable, averaging [$X], with minor adjustments reflecting inflation and supply considerations.
-
Medium-term (3-5 years): Prices could decline by 15-25%, primarily driven by biosimilar entries and increased payer negotiations.
-
Long-term (5+ years): Post-exclusivity, the drug's price may decrease by 40-60%, aligning with biosimilar parity prices. If new indications or formulations emerge, prices could stabilize at a higher level.
Market Entry and Development Opportunities
Investors and manufacturers should monitor biosimilar development pipelines targeting this product, with potential entry windows in the next 2-4 years. Strategic partnerships with payers and value-based agreements could also stabilize pricing and expand market share.
Innovative delivery mechanisms, such as patient-friendly formulations, could command premium pricing by enhancing adherence and clinical outcomes. Additionally, expanding indications through clinical trials could diversify revenue streams and justify higher price points.
Conclusion
NDC 72888-0183 operates within a dynamic pharmaceutical landscape shaped by patent protections, biosimilar competition, and evolving payer policies. While current pricing remains relatively stable, imminent biosimilar entries and regulatory reforms are poised to substantially influence future pricing trajectories.
Stakeholders should adopt flexible strategies that anticipate patent cliffs, foster value-based contracting, and invest in clinical differentiation to optimize market position and revenue potential.
Key Takeaways
-
Market Stability & Growth: The drug's current market size indicates a stable revenue stream, with moderate growth driven by increasing demand in its therapeutic segment.
-
Competitive Pressures: Patent expiry and early biosimilar competition forecast significant price reductions within the next 3-5 years, potentially decreasing prices by up to 50%.
-
Pricing Trends & Policy Impact: Current list prices are resilient but may face downward pressure from legislative reforms, payer negotiations, and biosimilar entries.
-
Strategic Opportunities: Engaging in value-based agreements, expanding indications, and enhancing formulations can preserve margins amid a competitive landscape.
-
Monitoring & Adaptation: Continuous tracking of regulatory actions, patent statuses, and biosimilar developments will be essential for refining pricing and market strategies.
FAQs
1. When is the patent expiration for NDC 72888-0183, and how will it affect pricing?
Patent expiration is projected around [year], after which biosimilar competitors are expected to enter the market, likely causing significant price reductions of 30-50%.
2. What are the main factors influencing the drug’s future price?
Patent status, biosimilar competition, regulatory policies, payer negotiation strategies, and clinical adoption rates are primary drivers affecting future pricing.
3. How do biosimilar entries impact the pricing of this drug?
Biosimilar launches typically lead to a 30-50% reduction in list prices for the reference product, intensifying competition and reducing profit margins.
4. Are there emerging therapeutic indications that could influence market dynamics?
Expansion into new indications via clinical trials can bolster demand and justify higher prices, potentially offsetting reductions from biosimilar competition.
5. What strategic actions can stakeholders take to optimize revenue from this drug?
Investing in clinical differentiation, securing value-based arrangement contracts, and preparing for biosimilar competition are critical steps to sustain market share and profitability.
Sources:
[1] FDA Labeling and Approval Data
[2] IQVIA Market Reports
[3] Patent and Exclusivity Data
[4] Industry News on Biosimilar Development
[5] Recent Legislation and Policy Briefs
More… ↓
